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Abstract
BACKGROUND—Research suggests that fetal exposure to magnesium sulfate before preterm birth
might reduce the risk of cerebral palsy.
METHODS—In this multicenter, placebo-controlled, double-blind trial, we randomly assigned
women at imminent risk for delivery between 24 and 31 weeks of gestation to receive magnesium
sulfate, administered intravenously as a 6-g bolus followed by a constant infusion of 2 g per hour,
or matching placebo. The primary outcome was the composite of stillbirth or infant death by 1 year
of corrected age or moderate or severe cerebral palsy at or beyond 2 years of corrected age.
RESULTS—A total of 2241 women underwent randomization. The baseline characteristics were
similar in the two groups. Follow-up was achieved for 95.6% of the children. The rate of the primary
outcome was not significantly different in the magnesium sulfate group and the placebo group (11.3%
and 11.7%, respectively; relative risk, 0.97; 95% confidence interval [CI], 0.77 to 1.23). However,
in a prespecified secondary analysis, moderate or severe cerebral palsy occurred significantly less
frequently in the magnesium sulfate group (1.9% vs. 3.5%; relative risk, 0.55; 95% CI, 0.32 to 0.95).
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The risk of death did not differ significantly between the groups (9.5% vs. 8.5%; relative risk, 1.12;
95% CI, 0.85 to 1.47). No woman had a life-threatening event.
CONCLUSIONS—Fetal exposure to magnesium sulfate before anticipated early preterm delivery
did not reduce the combined risk of moderate or severe cerebral palsy or death, although the rate of
cerebral palsy was reduced among survivors. (ClinicalTrials.gov number, NCT00014989.)
CEREBRAL PALSY IS CHARACTERIZED BY abnormal control of movement and posture that results in limitation
of activity. It is caused by nonprogressive damage or dysfunction of the developing fetal or
infant brain1 and is a leading cause of chronic childhood disability, with profound medical,
emotional, and economic consequences.2 Preterm birth is a risk factor for cerebral palsy, and
the magnitude of the risk is inversely correlated with gestational age at birth.3 During the past
20 to 30 years, the survival of infants born markedly preterm has improved dramatically, and
whereas some data suggest that the rate of cerebral palsy among survivors has recently declined,
4 other data suggest that the rate is unchanged5 or even increasing.6 At present, approximately
one third of cases of cerebral palsy are associated with early preterm birth.7
The possibility that magnesium sulfate administered to mothers delivering prematurely might
prevent cerebral palsy in their infants was first shown in a case–control study8 in which children
with cerebral palsy were much less likely to have been exposed to magnesium sulfate than
were control subjects (odds ratio, 0.14; 95% confidence interval [CI], 0.05 to 0.51). This
protective association has biologic plausibility, because magnesium may reduce vascular
instability, prevent hypoxic damage, and mitigate cytokine or excitatory amino acid damage,
all of which threaten the vulnerable preterm brain.9 We performed this study to test the
hypothesis that the administration of magnesium sulfate to women at high risk for early preterm
delivery would reduce the risk of cerebral palsy in their children.
METHODS
RECRUITMENT
This trial was conducted at 20 participating Eunice Kennedy Shriver National Institute of Child
Health and Human Development Maternal–Fetal Medicine Units Network sites across the
United States. Women were eligible if they were carrying singletons or twins at 24 through 31
weeks of gestation and were at high risk for spontaneous delivery because of rupture of the
membranes occurring at 22 through 31 weeks of gestation or because of advanced preterm
labor with dilatation of 4 to 8 cm and intact membranes. They were also eligible if an indicated
preterm delivery was anticipated within 2 to 24 hours (e.g., because of fetal growth restriction).
Women were not eligible if delivery was anticipated within less than 2 hours or if cervical
dilatation exceeded 8 cm; in such cases, the intervention was assumed to have little chance of
achieving an effect.10 Additional exclusion criteria included rupture of the membranes before
22 weeks, unwillingness of the obstetrician to intervene for the benefit of the fetus, major fetal
anomalies or death, maternal hypertension or preeclampsia, maternal contraindications to
magnesium sulfate (e.g., severe pulmonary disorders), and receipt of intravenous magnesium
sulfate within the previous 12 hours. The use of tocolytic drugs after randomization was
proscribed.
The duration of gestation was determined at entry to the trial according to a previously
described algorithm11 that uses the date of the last menstrual period (if reliable) and the results
of the earliest available ultrasound examination. The study was approved by the institutional
review boards of each clinical site and the data coordinating center. All participants gave
written informed consent before enrollment.
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Eligible, consenting women were randomly assigned in a double-blind fashion to receive either
intravenous magnesium sulfate (a loading dose of 6 g infused for 20 to 30 minutes, followed
by a maintenance infusion of 2 g per hour) or identical-appearing placebo. If delivery had not
occurred after 12 hours and was no longer considered imminent (e.g., if the woman was not
having regular uterine contractions), the infusion was discontinued and resumed when delivery
was deemed imminent again (e.g., when contractions developed). If at least 6 hours had passed
since the discontinuation of the study medication, another loading dose was given. Retreatment
was withheld if preeclampsia or eclampsia developed (in which case open-label magnesium
sulfate was administered for seizure prophylaxis), if it was thought that a delay in delivery in
order to administer retreatment would be detrimental to the mother or the fetus, or if the
gestational age had reached 34 weeks. Adherence to the protocol was monitored at each site
on an ongoing basis by the data coordinating center.
Group assignment was made according to a computer-generated random sequence,12 with
stratification according to clinical center and, in twin pregnancies, weeks of gestation (<28 or
≥28). Certified research nurses collected information on the mother's demographic features,
medical history, and social history at enrollment in the study. The nurses also obtained data on
neonatal and maternal outcomes at delivery and at scheduled follow-up visits when the infant
reached 6, 12, and 24 months of age (corrected for prematurity).
STUDY OUTCOMES
The primary outcome was the composite of stillbirth or infant death by 1 year of age or moderate
or severe cerebral palsy, as assessed at or beyond 2 years of age (with ages corrected for
prematurity). Death before 1 year of age was included because it is a competing outcome that
would preclude the assessment of cerebral palsy. We considered it possible to make a diagnosis
of cerebral palsy at 1 year, although our goal was to make this diagnosis on the basis of the 2-
year examination. Those infants who had a normal neurologic examination at 1 year, could
walk 10 steps independently, and had a bilateral pincer grasp were declared free of cerebral
palsy and, for the purpose of the primary outcome, were considered normal. No further
neurologic examination was required for these infants, since, by definition, cerebral palsy is
nonprogressive. We chose to include only moderate or severe cerebral palsy in the primary
outcome because cerebral palsy of this severity at or beyond 2 years of age portends lifelong
motor dysfunction, whereas mild cerebral palsy may resolve.13
An annually certified pediatrician or pediatric neurologist made a diagnosis of cerebral palsy
if two or more of the following three features were present: a delay of 30% or more in gross
motor developmental milestones (e.g., inability to sit without arm support by 9.5 months or
walk by 17 months of corrected age)14,15; abnormality in mus cle tone (e.g., scissoring), 4+
or absent deep-tendon reflexes, or movement abnormality (e.g., posturing or gait asymmetry);
or persistence of primitive reflexes or absence of protective reflexes.
When cerebral palsy was diagnosed, the Gross Motor Function Classification System
(GMFCS)16 was used to assess severity. At a corrected age of 2 years or more, a child who
was classified as functioning at GMFCS level 2 or above (GMFCS scores can range from 0 to
5, with higher scores indicating greater impairment; children with scores of 2 or above are
unable to walk independently) or who did not have the ability to grasp and release a 1-in. (2.54-
cm) block with both hands was considered to have at least moderately handicapping cerebral
palsy. Mild cerebral palsy was defined as a GMFCS grade of level 1, moderate cerebral palsy
as a grade of level of 2 or 3, and severe cerebral palsy as a grade of level 4 or 5.
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If children were not available within the 24-to-28-month window for the 2-year examination,
efforts were made to reschedule their appointments, regardless of their age. For 28 children
who were not evaluated at 2 years of age but were not declared free of cerebral palsy at the age
of 1 year, two pediatric neurologists who were unaware of the treatment assignment judged
whether the children had moderate or severe cerebral palsy on the basis of a review of the 1-
year examination.
Prespecified secondary outcomes included various maternal outcomes and complications;
adverse events potentially attributable to the study intervention; neonatal complications;
cerebral palsy at 2 years of age classified as mild, moderate, or severe; stillbirth; infant death;
and scores on the Bayley Scales of Infant Development II,17 administered at the 2-year
examination by a trained psychologist or psychometrist. Cranial ultrasound examinations were
performed on all neonates and were read centrally by three independent pediatric radiologists.
We performed nonprespecified analyses that were stratified according to whether
randomization occurred before 28 weeks or at 28 or more weeks of gestation, whether the
gestation was singleton or twin, and whether the fetus had been previously exposed to
magnesium sulfate. We also performed an analysis of the primary outcome and its components,
excluding infants who had major congenital anomalies that were discovered after birth. Before
this analysis, a single clinical geneticist (without knowledge of study-group assignment)
classified anomalies as major or minor on the basis of a review of the medical records according
to standard criteria.18
STATISTICAL ANALYSIS
We estimated that the primary outcome would occur in 14% of the placebo group, on the
assumption of a rate of death of 6%,19 and that the rate of moderate or severe cerebral palsy
among survivors would be 8%.20 Thus, an equally divided sample of 2000 was deemed
sufficient for the detection of a 30% reduction in this outcome, with a type I error (two-sided)
of 5% and a power of at least 80%. On the assumption of a 10% rate of loss to follow-up, we
established a target sample size of 2200.
The data from all patients were analyzed according to the group to which they were randomly
assigned, regardless of whether they received the study medication. In any given pregnancy,
the primary outcome could be credited only once (i.e., cerebral palsy followed by death counted
for only one primary outcome). For all analyses of maternal and primary outcomes, including
the components of the primary outcome, the unit of analysis was the pregnancy (i.e., a twin
pregnancy was credited with an event if it occurred in either twin). Continuous variables were
compared with the use of the Wilcoxon rank-sum test, and categorical variables with the chi-
square test, Fisher's exact test, or the Mantel–Haenszel chi-square test for trend. The Breslow–
Day test was used to test for heterogeneity of treatment effects across strata. For all other
neonatal outcomes, log-binomial regression was performed. The unit of analysis was the
neonate, with generalized estimating equations used to adjust for the clustering of neonates
within pregnancies. Analyses were performed with the use of SAS software, version 8.2.
The group sequential method of Lan and DeMets with the modified O'Brien–Fleming spending
function was used for adjustment of the significance level in interim analyses.21 Four interim
analyses were performed; in the final analysis of the primary outcome, two-tailed P values of
less than 0.043 were considered to indicate statistical significance. However, since the
adjustment is minimal, we reported 95% confidence intervals. For all outcomes other than
moderate or severe cerebral palsy and death, a nominal P value of less than 0.05 was considered
to indicate statistical significance, and no adjustments were made for multiple comparisons.
An independent data and safety monitoring committee monitored the trial and reviewed the
interim results.
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From December 1997 through May 2004, a total of 2241 eligible women were enrolled (Fig.
1). The baseline characteristics of the two groups were similar (Table 1). The primary outcome
was assessed for 95.6% of fetuses. Ninety-five percent of examinations for cerebral palsy were
completed by 32 months of corrected age. In three children who did not have an examination
at 2 years, moderate or severe cerebral palsy was diagnosed on the basis of the 1-year
examination. The baseline characteristics of the women whose fetuses were lost to follow-up
did not differ significantly between the two study groups.
Adherence to the assigned intervention was high, and off-protocol use of magnesium sulfate
for tocolysis was infrequent (1.4%) (Fig. 1). The median total dose of the study drug received
by women in the magnesium sulfate group was 31.5 g (interquartile range, 29.0 to 44.6). Six
hundred thirty-nine women (28.5%) were not eligible for retreatment. Of the 1602 women
(71.5%) who were eligible for retreatment, 947 (59.1%) were receiving the study drug at
delivery. The most common reasons that indicated retreatment did not occur were staff error
and urgent cesarean delivery.
The primary composite outcome of moderate or severe cerebral palsy or death occurred in 118
(11.3%) of the 1041 pregnancies in which the mothers were assigned to receive magnesium
sulfate and 128 (11.7%) of the 1095 pregnancies in which the mothers were assigned to receive
placebo (relative risk, 0.97; 95% CI, 0.77 to 1.23) (Table 2). The risk of giving birth to an infant
subsequently receiving a diagnosis of moderate or severe cerebral palsy was lower among
women in the magnesium sulfate group than among women in the placebo group (1.9% vs.
3.5%; relative risk, 0.55; 95% CI, 0.32 to 0.95; P = 0.03), whereas the risk of stillbirth or infant
death was slightly higher in the magnesium sulfate group than in the placebo group (9.5% vs.
8.5%; relative risk, 1.12; 95% CI, 0.85 to 1.47; P = 0.41). Exclusion of children with major
congenital anomalies discovered after birth slightly lowered the relative risk of the composite
primary outcome and attenuated the relative risk of death but had minimal effect on the relative
risk of cerebral palsy (Table 2). Scores on the Bayley scales did not significantly differ between
the two groups.
Cerebral palsy was diagnosed in 41 children from 40 of 942 pregnancies in the magnesium
sulfate group (4.2%) and in 74 children from 73 of 1002 pregnancies in the placebo group
(7.3%, P = 0.004). The percentages of mild, moderate, and severe cerebral palsy (not including
diagnoses at 1 year) were 2.2%, 1.5%, and 0.5%, respectively, in the magnesium sulfate group
and 3.7%, 2.0%, and 1.6%, respectively, in the placebo group (P for trend = 0.004). The results
of the stratified analyses, including those of singleton and twin pregnancies, were broadly
consistent with those of the primary analysis (P>0.05 for all comparisons with the use of the
Breslow–Day test) (Table 3).
Obstetrical outcomes were similar between the groups (Table 4). Adverse events, such as
flushing or sweating, were more frequent in the magnesium sulfate group. Discontinuation of
study medication was more frequent in the magnesium sulfate group than in the control group
(4.2% vs. 1.4%, P<0.001). However, there were no life-threatening events or maternal deaths
in either group. For a wide variety of neonatal outcomes, no significant differences between
the groups were noted (Table 5).
DISCUSSION
We found that treatment with magnesium sulfate in women at imminent risk for delivery
between 24 and 31 weeks of gestation had no significant effect on the primary composite
outcome of moderate or severe cerebral palsy or death. Magnesium sulfate was associated with
a slight but non-significant increase in the risk of fetal or infant death and a significant decrease
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in the risk of moderate or severe cerebral palsy among surviving children. The exclusion of
infants with major congenital malformations discovered after birth attenuated the increase in
the risk of death.
Two previous randomized, placebo-controlled trials of antenatal magnesium sulfate for fetal
neuroprotection are noteworthy. Crowther et al.22 studied 1062 women at imminent risk for
delivery before 30 weeks of gestation. Stillbirth or death of their infants before the age of 2
years was less frequent, albeit not significantly so, among women assigned to receive
magnesium sulfate than among those assigned to receive placebo (13.8% vs. 17.1%; relative
risk, 0.83; 95% CI, 0.64 to 1.09). Substantial gross motor dysfunction (diagnosed according
to criteria essentially identical to our criteria for moderate or severe cerebral palsy) was
significantly less frequent among surviving children in the magnesium sulfate group (3.4% vs.
6.6%; relative risk, 0.51; 95% CI, 0.29 to 0.91). Marret et al.23 recently reported 2-year
outcomes of a trial that involved 573 mothers. Infants of women assigned to receive magnesium
sulfate had nonsignificantly lower rates of death (9.7% vs. 11.3%; relative risk, 0.85; 95% CI,
0.55 to 1.32) and of cerebral palsy among survivors (7.0% vs. 10.2%; relative risk, 0.69; 95%
CI, 0.41 to 1.16).
Preterm labor with intact membranes was the predominant indication for enrollment in those
two trials. In our study, such a diagnosis was often considered an indication for tocolysis by
the managing clinicians, and thus preterm premature rupture of membranes predominated.
In both the trial by Crowther et al.22 and the present trial, the 95% confidence interval around
the reduced relative risk of moderate or severe cerebral palsy (what Crowther et al. refer to as
“substantial gross motor dysfunction”) does not include 1; however, because this outcome
alone is viewed as a secondary outcome, the result is not statistically compelling.
Other randomized trials of magnesium sulfate administered to mothers for fetal neuroprotection
have been much less informative. One small study of 150 women was conducted as a feasibility
trial and did not report follow-up rates24,25; its methodologic limitations have been previously
detailed.26-30 Another trial was not primarily designed to address the question of fetal
neuroprotection, and the follow-up rate was low.31
Neither the present trial nor the trials of Crowther et al. or Marret et al. demonstrated a
statistically significant effect of magnesium sulfate on the composite outcome of death or
cerebral palsy. Although composite outcomes have their shortcomings,32 in a trial of this nature
they are essential, since, as Crowther et al. noted,33 “a child cannot have motor dysfunction at
2 years if he or she has already died.” An additional reason to include death in the composite
outcome is that the small study by Mittendorf et al.24 suggested that magnesium sulfate
significantly increased mortality; this finding was aggressively promoted,25 even though we
and others disputed it.26-30
Infants who are at high risk for prematurity-associated cerebral palsy are at even greater risk
for death. In our trial, death was three to four times as common as moderate or severe cerebral
palsy; this end point dominates the combined end point. Thus, even when the rate of death does
not differ significantly between groups (as in the three most pertinent trials), the potential for
a difference in the rates of cerebral palsy to result in a significant difference in the rate of the
composite outcome is small unless the sample is very large. We anticipated a higher rate of
moderate or severe cerebral palsy in planning the trial than we actually observed, and this
limited our statistical power to detect a difference in the composite outcome. We speculate that
our rigorous diagnostic criteria accounted for this lower rate.
Overall, our study showed no significant effect of magnesium sulfate on the combined end
point of death or moderate or severe cerebral palsy. However, consistent with the results of
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previous trials, our findings suggest that magnesium sulfate may reduce the chance that cerebral
palsy will subsequently be diagnosed in a child who was at high risk for preterm birth.
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Table 1
Baseline Characteristics of the Mothers.*
Characteristic Magnesium Sulfate (N = 1096) Placebo (N = 1145)
Weeks of gestation at randomization 28.3±2.5 28.2±2.4
Maternal age — yr 26.1±6.3 25.9±6.2
Maternal prepregnancy body-mass index† 26.0±6.7 26.4±6.9
Maternal race or ethnic group — no. (%)‡
    Black 483 (44.1) 495 (43.2)
    White 404 (36.9) 418 (36.5)
    Hispanic 184 (16.8) 206 (18.0)
    Other 25 (2.3) 26 (2.3)
Married — no./total no. (%) 549/1094 (50.2) 530/1142 (46.4)
Educational level — yr 11.8±2.5 11.8±2.5
Nulliparous — no. (%) 391 (35.7) 414 (36.2)
Previous preterm delivery — no. (%) 292 (26.6) 310 (27.1)
No prenatal care — no. (%) 78 (7.1) 88 (7.7)
Smoking during pregnancy — no. (%) 299 (27.3) 319 (27.9)
Alcohol use during pregnancy — no. (%) 93 (8.5) 96 (8.4)
Illicit-substance use during pregnancy — no. (%) 108 (9.9) 104 (9.1)
Twin gestation — no. (%) 92 (8.4) 111 (9.7)
Magnesium sulfate before enrollment — no. (%) 201 (18.3) 218 (19.0)
Qualifying eligibility criterion
    Premature rupture of membranes — no. (%) 947 (86.4) 995 (86.9)
        Time since rupture — hr§
            Median 25.2 24.4
            Interquartile range 10.7–61.1 10.8–62.9
    Advanced preterm labor — no. (%) 116 (10.6) 114 (10.0)
        Cervical dilatation — cm 4.8±1.2 4.6±1.0
    Indicated preterm delivery — no. (%) 33 (3.0) 36 (3.1)
*
Plus-minus values are means ±SD. P>0.05 for all between-group comparisons.
†
The body-mass index is the weight in kilograms divided by the square of the height in meters. Values were unavailable for 111 mothers in the
magnesium sulfate group and 128 in the placebo group.
‡
Race or ethnic group was self-reported. Percentages may not total 100 because of rounding.
§
Values were unavailable for 46 mothers in the magnesium sulfate group and 50 in the placebo group.
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Table 2
Outcomes Assessed at Follow-up.
Outcome Magnesium
Sulfate (N = 1041)





        Moderate or severe
cerebral palsy or death*
118/1041 (11.3) 128/1095 (11.7) 0.97 (0.77–1.23) 0.80
        Moderate or severe
cerebral palsy alone
20/1041 (1.9) 38/1095 (3.5) 0.55 (0.32–0.95) 0.03




        Moderate or severe
cerebral palsy or death*
100/997 (10.0) 117/1063 (11.0) 0.91 (0.71–1.17) 0.47
        Moderate or severe
cerebral palsy alone
18/997 (1.8) 34/1063 (3.2) 0.56 (0.32–0.99) 0.04
        Death alone 83/997 (8.3) 86/1063 (8.1) 1.03 (0.77–1.37) 0.85
Scores on the Bayley
Scales of Infant
Development
        Psychomotor
Development Index <70
134/876 (15.3) 144/919 (15.7) 0.98 (0.79–1.21) 0.83
        Psychomotor
Development Index <85
299/876 (34.1) 315/919 (34.3) 1.00 (0.88–1.13) 0.95
        Mental Development
Index <70
165/876 (18.8) 171/919 (18.6) 1.01 (0.83–1.23) 0.90
        Mental Development
Index <85
406/876 (46.3) 427/919 (46.5) 1.00 (0.90–1.10) 0.96
*
In one twin pregnancy in the magnesium sulfate group and in three twin pregnancies in the placebo group, one of the fetuses was stillborn or died
as an infant, whereas the other survived and subsequently received a diagnosis of moderate or severe cerebral palsy. Thus, the number of pregnancies
associated with death alone and the number of pregnancies associated with moderate or severe cerebral palsy alone do not add up to the number of
pregnancies associated with moderate or severe cerebral palsy or death.
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Table 3
Stratified Analyses of the Primary Outcome and Its Components.*




    Weeks of gestation at
randomization
        <28 89/442 (20.1) 105/496 (21.2) 0.95 (0.74–1.22)
        ≥28 29/599 (4.8) 23/599 (3.8) 1.26 (0.74–2.15)
    Magnesium sulfate
treatment before
randomization
        Yes 27/192 (14.1) 26/210 (12.4) 1.14 (0.69–1.88)
        No 91/849 (10.7) 102/885 (11.5) 0.93 (0.71–1.21)
    Singleton or twin
pregnancy
        Singleton 97/950 (10.2) 103/985 (10.5) 0.98 (0.75–1.27)
        Twin 21/91 (23.1) 25/110 (22.7) 1.02 (0.61–1.69)
Moderate or severe
cerebral palsy
    Weeks of gestation at
randomization
        <28 12/442 (2.7) 30/496 (6.0) 0.45 (0.23–0.87)
        ≥28 8/599 (1.3) 8/599 (1.3) 1.00 (0.38–2.65)
    Magnesium sulfate
treatment before
randomization
        Yes 6/192 (3.1) 11/210 (5.2) 0.60 (0.23–1.58)
        No 14/849 (1.6) 27/885 (3.1) 0.54 (0.29–1.02)
    Singleton or twin
pregnancy
        Singleton 14/950 (1.5) 28/985 (2.8) 0.52 (0.27–0.98)
        Twin 6/91 (6.6) 10/110 (9.1) 0.73 (0.27–1.92)
Fetal or infant death
    Weeks of gestation at
randomization
        <28 78/442 (17.6) 78/496 (15.7) 1.12 (0.84–1.49)
        ≥28 21/599 (3.5) 15/599 (2.5) 1.40 (0.73–2.69)
    Magnesium sulfate
treatment before
randomization
        Yes 21/192 (10.9) 15/210 (7.1) 1.53 (0.81–2.88)
        No 78/849 (9.2) 78/885 (8.8) 1.04 (0.77–1.41)
    Singleton or twin
pregnancy
        Singleton 83/950 (8.7) 75/985 (7.6) 1.15 (0.85–1.55)
        Twin 16/91 (17.6) 18/110 (16.4) 1.07 (0.58–1.98)
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*
The primary outcome was the composite of stillbirth or infant death by 1 year of corrected age or moderate or severe cerebral palsy at or beyond 2
years of corrected age. P>0.05 for all comparisons (Breslow–Day test).
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Table 4
Maternal Obstetrical Outcomes and Adverse Events Potentially Attributable to the Study Intervention.*
Variable Magnesium Sulfate (N =
1096)
Placebo (N = 1145) P Value
Obstetrical outcomes
    Gestational age at delivery — wk 29.8±3.1 29.7±3.1 0.32
    Receipt of antenatal corticosteroids —
no. (%)
1062 (96.9) 1116 (97.5) 0.49
    Chorioamnionitis — no./total no. (%) 127/1086 (11.7) 131/1141 (11.5) 0.88
    Cesarean delivery — no./total no. (%) 417/1086 (38.4) 448/1141 (39.3) 0.68
    Endometritis — no./total no. (%) 74/1086 (6.8) 80/1141 (7.0) 0.85
    Pulmonary edema — no./total no. (%) 8/1086 (0.7) 3/1141 (0.3) 0.11
Adverse events†
    Any adverse event — no./total no. (%) 833/1078 (77.3) 140/1125 (12.4) <0.001
    Flushing — no./total no. (%) 703/1078 (65.2) 74/1125 (6.6) <0.001
    Sweating — no./total no. (%) 307/1078 (28.5) 28/1125 (2.5) <0.001
    Pain or burning at intravenous site —
no./total no. (%)
259/1078 (24.0) 29/1125 (2.6) <0.001
    Nausea or vomiting — no./total no. (%) 166/1078 (15.4) 19/1125 (1.7) <0.001
    Respiratory depression — no./total no.
(%)‡
7/1078 (0.6) 3/1125 (0.3) 0.22
    Infusion stopped because of adverse
event — no./total no. (%)
45/1078 (4.2) 16/1125 (1.4) <0.001
*
Plus–minus values are means ±SD. Except for gestational age, which was established systematically by algorithm, data on outcomes are based on
clinical diagnoses in the medical records, and data on adverse events are based on notations in the medical records or direct report by the participant
to a research nurse.
†
Adverse events are reported only for the mothers who received study medication.
‡
All cases either were self-limited or responded to diuresis and supplemental oxygen.
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Table 5
Selected Neonatal Outcomes According to Treatment Group.*
Outcome Magnesium





Birth weight — g 1410±567 1424±577
5-Minute Apgar score <7 — no./total no.
(%)
212/1171 (18.1) 229/1240 (18.5) 0.96 (0.81–1.15)
Resuscitation in the delivery room —
no./total no. (%)†
0.92 (0.83–1.02)
    None 194/1172 (16.6) 197/1244 (15.8)
    Oxygen bag, mask, or both 524/1172 (44.7) 520/1244 (41.8)
    Intubation 412/1172 (35.2) 487/1244 (39.1)
    Chest compressions 42/1172 (3.6) 40/1244 (3.2)
Hypotension treated with vasopressors
— no./total no. (%)
248/1171 (21.2) 265/1244 (21.3) 1.00 (0.85–1.17)
Generalized hypotonicity — no./total no.
(%)
85/1171 (7.3) 88/1244 (7.1) 1.00 (0.75–1.35)
Culture-proven sepsis — no./total no.
(%)
200/1171 (17.1) 220/1244 (17.7) 0.97 (0.81–1.16)
Necrotizing enterocolitis — no./total no.
(%)
116/1171 (9.9) 94/1244 (7.6) 1.27 (0.97–1.66)
Retinopathy of prematurity — no./total
no. (%)
263/1171 (22.5) 283/1244 (22.7) 0.98 (0.84–1.15)
Respiratory distress syndrome — no./
total no. (%)
585/1171 (50.0) 656/1244 (52.7) 0.96 (0.88–1.04)
Mechanical ventilation — no./total no.
(%)
613/1171 (52.3) 709/1244 (57.0) 0.92 (0.85–0.99)
Bronchopulmonary dysplasia — no./
total no. (%)
213/1171 (18.2) 218/1244 (17.5) 1.03 (0.86–1.23)
Patent ductus arteriosus — no./total no.
(%)
151/1171 (12.9) 173/1244 (13.9) 0.95 (0.77–1.18)
Seizures — no./total no. (%) 23/1171 (2.0) 29/1244 (2.3) 0.79 (0.45–1.38)
Findings on cranial ultrasonography —
no./total no. (%)
    Any intraventricular hemorrhage 218/1112 (19.6) 252/1184 (21.3) 0.91 (0.78–1.08)
    Grade III or IV intraventricular
hemorrhage
23/1112 (2.1) 38/1184 (3.2) 0.64 (0.38–1.06)
    Periventricular leukomalacia 21/1112 (1.9) 27/1184 (2.3) 0.83 (0.47–1.45)
Major congenital anomaly — no./total
no. (%)
47/1112 (4.0) 33/1184 (2.7) 1.51 (0.97–2.33)
*
Plus–minus values are means ±SD. Except for intraventricular hemorrhage and periventricular leukomalacia (which were diagnosed centrally by
three independent pediatric radiologists), data on complications are based on clinical diagnoses in the medical record.
†
The relative risk is given for a composite of intubation or chest compressions.
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